Descamps C, Van Waeleghem J P, Ysebaert D
Nephrology Unit, University Hospital, Antwerp.
EDTNA ERCA J. 1996 Jul-Sep;22(3):22-6.
The establishment of an adequate recombinant erythropoietin (epo) treatment for haemodialysis patients has challenged nephrology workers for the last 5 years. Starting with epo, it was quickly clear that its management was complex and a lot of conditions were involved in its effective application.
在过去5年里，为血液透析患者建立适当的重组促红细胞生成素（epo）治疗方法一直是肾脏病学工作者面临的挑战。从促红细胞生成素开始，很快就清楚其管理很复杂，并且其有效应用涉及很多条件。
